血小板增多症在婦癌的檢視

Thrombocytosis in Women with Gynecologic Cancer

約1/3癌症患者在被診斷出，甚至診斷出前，就有血小板增多的現象。最近，在許多不同癌症的研究中，發現血小板增多不但可作為血液中診斷惡性腫瘤標記，並與患者的預後有關。在婦科癌症中，包括卵巢、子宮頸、子宮內膜、和外陰癌，都曾有關於血小板數目的研究。有些報告指出在局部晚期的子宮頸癌和子宮內膜癌中，血小板增多症可能為一獨立的不良預後因子。但在卵巢癌患者中，血小板增多與生存時間的結論則不盡相同。由於這些研究多為回顧性，因此，對血小板增多症與臨床結果的關係，實有進行大規模前瞻性研究的必要。

Nearly one-third of cancer patients are found to have thrombocytosis at diagnosis and before treatment. Recently, there has been increasing interest in the incidence of thrombocytosis in various cancers and its association with patient outcome. In gynecologic cancers, preoperative elevations in platelet counts have been described for ovarian, cervical, endometrial, and vulvar cancer. Several studies suggest that thrombocytosis may be an independent poor prognostic factor in locally advanced cervical and endometrial cancers. Various studies investigating the presence of thrombocytosis in ovarian cancers yield inconsistent results about the association between thrombocytosis and survival. More prospective trials are needed to elucidate the correlation between the thrombocytosis and clinical outcome.